Key facts
- MediBeacon’s last known valuation is $300.0M (Sep 2019).
- It has raised $110.6M across 10 recorded rounds; the latest was Early Stage VC ($16.1M) in Aug 2023.
- Notable investors include Gates Foundation, Jump Capital, BioGenerator Ventures, Missouri Technology Corporation, NEXT Mannheim — 16 tracked in total.
- MediBeacon has filed 10 Form Ds with the SEC since 2015, most recently Jan 2025 ($16.1M sold to 38 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 10 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for MediBeacon
Funding rounds
10 roundsAbout MediBeacon
Developer of fluorescent tracer-agent-based systems designed to help provide a vital and actionable measurement of organ function. The company's monitoring system uses an optical skin sensor combined with a proprietary agent that glows in the presence of light, enabling intensive care units and hospitals to continuously monitor patients' kidney and other vital organ functions in real-time to improve patient outcomes in the ICU and the operating suite, alongside achieving optimal dosing strategies.
- Sector
- Healthcare
- HQ
- Saint Louis, MO, United States
- Founded
- 2011
- Employees
- 29
- Website
- medibeacon.com/
- Ownership
- Privately Held (backing)
MediBeacon doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MediBeacon shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MediBeacon in its N-PORT filings yet. We sweep new filings monthly.